Invitrogen™ Vonlerizumab Recombinant Monoclonal Antibody

Vonlerizumab, also known as an anti-human CD134 (OX40) monoclonal antibody, is extensively studied for its targeted immunomodulatory function. TNFRSF4, also known as OX40 or CD134, is a gene encoding a protein that belongs to the tumor necrosis factor receptor (TNFR) superfamily. This receptor is primarily expressed on activated CD4 and CD8 T cells and serves as a co-stimulatory molecule involved in the regulation of immune responses. Upon binding with its ligand, OX40L (CD252), OX40 transmits signals that promote T cell proliferation, survival, and cytokine production, thereby enhancing the immune response. The expression of the OX40 gene is tightly controlled and can be upregulated by chromatin remodeling in T cells. OX40 signaling plays a crucial role in the accumulation of protective T cells during anti-viral and anti-tumor immune responses and is being explored as a therapeutic target in both autoimmune diseases and cancer immunotherapy due to its ability to modulate T cell-mediated immune functions.